Skip to main content
Clinical Trials/DRKS00004794
DRKS00004794
Completed
Not Applicable

Prospective observational study to assess the efficacy and tolerability of axiplatin® using different timing regimens and doses in clinical practice in patients with stage III colon carcinoma (Dukes C) or metastatic colorectal carcinoma (short title: FREDOS). - FREDOS

AxioNovo GmbH0 sites575 target enrollmentMarch 6, 2013

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
C18
Sponsor
AxioNovo GmbH
Enrollment
575
Status
Completed
Last Updated
last year

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
March 6, 2013
End Date
December 31, 2022
Last Updated
last year
Study Type
Observational
Sex
All

Investigators

Eligibility Criteria

Inclusion Criteria

  • Patients with stage III colon carcinoma (Dukes C) for whom therapy with axiplatin® is indicated according to the SmPC.
  • \- Patients with metastatic colorectal cancer for whom therapy with axiplatin® is indicated according to the SmPC.
  • \- Age: older than 18 years
  • \- Axiplatin is used in therapy.
  • \- A hand\-dated and signed informed consent is available.
  • \- Therapy was selected independent of potential study inclusion.

Exclusion Criteria

  • \- Contraindications to the use of Epirubicin LIV Pharma according to the SmPC.
  • \- The current therapy was started more than 12 weeks ago.
  • \- The patient is participating in a clinical trial at the same time.

Outcomes

Primary Outcomes

Not specified

Similar Trials